PMID- 27109558
OWN - NLM
STAT- MEDLINE
DCOM- 20170201
LR  - 20170201
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 128 Suppl 1
DP  - 2016 Oct
TI  - Increasing Patient Acceptance and Adherence Toward Insulin.
PG  - 11-20
LID - 10.1080/00325481.2016.1177969 [doi]
AB  - Because of the progressive nature of type 2 diabetes mellitus (T2DM), the 
      majority of patients will need insulin to achieve and maintain glycemic control. 
      By maintaining glycemic control, patients will avoid acute osmotic symptoms of 
      hyperglycemia, instability in plasma glucose (PG) over time, and prevent or delay 
      the development of diabetes complications without adversely affecting quality of 
      life. Despite recommendations for initiating insulin therapy, both patient and 
      health system barriers stand in the way. To develop confidence in individualizing 
      patient therapy and maximize outcomes for patients with T2DM, healthcare 
      practitioners (HCPs) were updated on recommendations and clinical evidence 
      supporting when to initiate insulin therapy, strategies for overcoming provider 
      and patient barriers for initiating insulin therapy, and the safety and efficacy 
      of current and emerging insulin therapy and delivery technology for patients with 
      T2DM.
FAU - Riddle, Matthew
AU  - Riddle M
AD  - a Division of Endocrinology, Diabetes & Clinical Nutrition , Oregon Health & 
      Science University , Portland , OR , USA.
FAU - Peters, Anne
AU  - Peters A
AD  - b USC Clinical Diabetes Programs , Keck School of Medicine of USC , Los Angeles , 
      CA , USA.
FAU - Funnell, Martha
AU  - Funnell M
AD  - c Department of Learning Health Sciences , University of Michigan Medical School 
      , Ann Arbor , MI , USA.
LA  - eng
PT  - Journal Article
DEP - 20160422
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Blood Glucose/analysis
MH  - *Diabetes Complications/physiopathology/prevention & control
MH  - *Diabetes Mellitus, Type 2/blood/diagnosis/drug therapy/psychology
MH  - Disease Progression
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Insulin/pharmacology/therapeutic use
MH  - *Medication Adherence/psychology/statistics & numerical data
MH  - *Quality of Life
MH  - Time-to-Treatment
OTO - NOTNLM
OT  - Type 2 diabetes mellitus (T2DM)
OT  - insulin adherence
OT  - insulin barriers
OT  - insulin delivery systems
OT  - insulin therapy
EDAT- 2016/04/26 06:00
MHDA- 2017/02/02 06:00
CRDT- 2016/04/26 06:00
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2017/02/02 06:00 [medline]
AID - 10.1080/00325481.2016.1177969 [doi]
PST - ppublish
SO  - Postgrad Med. 2016 Oct;128 Suppl 1:11-20. doi: 10.1080/00325481.2016.1177969. 
      Epub 2016 Apr 22.